JP5592277B2 - エプスタイン−バーウイルス（ｅｂｖ）再活性化のインビトロ診断のためのｚｅｂｒａタンパク質由来合成ペプチドの使用 - Google Patents
エプスタイン−バーウイルス（ｅｂｖ）再活性化のインビトロ診断のためのｚｅｂｒａタンパク質由来合成ペプチドの使用 Download PDFInfo
- Publication number
- JP5592277B2 JP5592277B2 JP2010550179A JP2010550179A JP5592277B2 JP 5592277 B2 JP5592277 B2 JP 5592277B2 JP 2010550179 A JP2010550179 A JP 2010550179A JP 2010550179 A JP2010550179 A JP 2010550179A JP 5592277 B2 JP5592277 B2 JP 5592277B2
- Authority
- JP
- Japan
- Prior art keywords
- ebv
- polypeptide
- antibody
- zebra
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 110
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 101
- 241000283070 Equus zebra Species 0.000 title claims abstract description 77
- 238000000338 in vitro Methods 0.000 title claims abstract description 19
- 230000007420 reactivation Effects 0.000 title claims description 36
- 108090000623 proteins and genes Proteins 0.000 title abstract description 42
- 102000004169 proteins and genes Human genes 0.000 title abstract description 38
- 241000701044 Human gammaherpesvirus 4 Species 0.000 title description 74
- 238000003745 diagnosis Methods 0.000 title description 5
- 229920001184 polypeptide Polymers 0.000 claims abstract description 95
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims abstract description 30
- 239000012472 biological sample Substances 0.000 claims abstract description 30
- 230000007419 viral reactivation Effects 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 33
- 238000001514 detection method Methods 0.000 claims description 27
- 230000001575 pathological effect Effects 0.000 claims description 25
- 238000002965 ELISA Methods 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 238000008157 ELISA kit Methods 0.000 claims description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 10
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 10
- 230000007170 pathology Effects 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 description 55
- 229940024606 amino acid Drugs 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 43
- 101000693440 Anaplasma phagocytophilum (strain HZ) SUMOylated effector protein AmpA Proteins 0.000 description 37
- 101001030080 Diplobatis ommata Major vault protein Proteins 0.000 description 37
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 37
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 36
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 16
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 16
- 229960002429 proline Drugs 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 13
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 10
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- 208000032420 Latent Infection Diseases 0.000 description 8
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 8
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 208000011691 Burkitt lymphomas Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101150113776 LMP1 gene Proteins 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 108010051791 Nuclear Antigens Proteins 0.000 description 2
- 102000019040 Nuclear Antigens Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- RAXBNPHSJQAKOG-SOGCEIGASA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-4-methyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]pentanoyl]amino]pentanoyl]amino]pentanoyl]amino]-3-hydroxybutanoyl]amino Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 RAXBNPHSJQAKOG-SOGCEIGASA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101150078891 BRLF1 gene Proteins 0.000 description 1
- 101150009389 BZLF1 gene Proteins 0.000 description 1
- RHTUSLLDUCKMQV-YIZMJDBSSA-N C[S+](CC[C@@H](C(O)=O)N)C[C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(N)=C2N=C1.N[C@@H](CCS)C([O-])=O Chemical compound C[S+](CC[C@@H](C(O)=O)N)C[C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(N)=C2N=C1.N[C@@H](CCS)C([O-])=O RHTUSLLDUCKMQV-YIZMJDBSSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 1
- 108010006763 GSK peptide Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/05—Epstein-Barr virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290224.8 | 2008-03-10 | ||
| EP08290224A EP2101177A1 (en) | 2008-03-10 | 2008-03-10 | Use of synthetic peptide derived from zebra protein for the in vitro diagnosis of the epstein-barr virus (EBV) reactivation |
| PCT/EP2009/052798 WO2009112497A1 (en) | 2008-03-10 | 2009-03-10 | Use of synthetic peptide derived from zebra protein for the in vitro diagnosis of the epstein-barr virus (ebv) reactivation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513759A JP2011513759A (ja) | 2011-04-28 |
| JP2011513759A5 JP2011513759A5 (enExample) | 2011-06-16 |
| JP5592277B2 true JP5592277B2 (ja) | 2014-09-17 |
Family
ID=39595705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550179A Expired - Fee Related JP5592277B2 (ja) | 2008-03-10 | 2009-03-10 | エプスタイン−バーウイルス（ｅｂｖ）再活性化のインビトロ診断のためのｚｅｂｒａタンパク質由来合成ペプチドの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110076671A1 (enExample) |
| EP (2) | EP2101177A1 (enExample) |
| JP (1) | JP5592277B2 (enExample) |
| CN (1) | CN102016586B (enExample) |
| AT (1) | ATE530913T1 (enExample) |
| CA (1) | CA2718245C (enExample) |
| ES (1) | ES2375095T3 (enExample) |
| MY (1) | MY156432A (enExample) |
| WO (1) | WO2009112497A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2983482B1 (fr) * | 2011-12-05 | 2017-10-20 | Univ Joseph Fourier | Utilisation d'au moins un biomarqueur pour le pronostic ou le diagnostic in vitro d'episodes lymphoproliferatifs associes au virus d'epstein-barr (ebv) |
| WO2014025254A1 (en) | 2012-08-10 | 2014-02-13 | Stichting Vu-Vumc | Ebv markers and systemic lupus erythematosus |
| CN109679975B (zh) * | 2019-01-23 | 2020-12-08 | 济宁医学院 | 一种改造bzlf1和改造lmp1的融合基因及其应用 |
| CN111826412A (zh) * | 2020-06-02 | 2020-10-27 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种高通量检测eb病毒感染效率/抗体阻断eb病毒感染效率的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2149822T3 (es) * | 1992-09-15 | 2000-11-16 | Ortho Diagnostic Systems Inc | Peptidos inmunorreactivos procedentes del virus de epstein-barr. |
| FR2728904B1 (fr) * | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| ATE211172T1 (de) * | 1995-06-06 | 2002-01-15 | Organon Teknika Bv | Epstein-barr viruspeptide, und antikörper gegen diese peptide |
| JPH11511853A (ja) * | 1996-03-29 | 1999-10-12 | オルソ ダイアグノスティック システムズ インク | エプスタイン・バーウイルス関連疾患の診断法 |
| FR2791142B1 (fr) * | 1999-03-17 | 2001-06-22 | Univ Grenoble 1 | Utilisation de la brefeldine a pour augmenter l'effet de presentation d'antigenes exogenes par les cpa |
| WO2007097820A2 (en) * | 2005-11-18 | 2007-08-30 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
-
2008
- 2008-03-10 EP EP08290224A patent/EP2101177A1/en not_active Withdrawn
-
2009
- 2009-03-10 EP EP09719883A patent/EP2269069B1/en not_active Not-in-force
- 2009-03-10 WO PCT/EP2009/052798 patent/WO2009112497A1/en not_active Ceased
- 2009-03-10 US US12/921,804 patent/US20110076671A1/en not_active Abandoned
- 2009-03-10 JP JP2010550179A patent/JP5592277B2/ja not_active Expired - Fee Related
- 2009-03-10 MY MYPI2010004281A patent/MY156432A/en unknown
- 2009-03-10 AT AT09719883T patent/ATE530913T1/de not_active IP Right Cessation
- 2009-03-10 CA CA2718245A patent/CA2718245C/en not_active Expired - Fee Related
- 2009-03-10 ES ES09719883T patent/ES2375095T3/es active Active
- 2009-03-10 CN CN200980115338.9A patent/CN102016586B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2269069B1 (en) | 2011-10-26 |
| WO2009112497A1 (en) | 2009-09-17 |
| ATE530913T1 (de) | 2011-11-15 |
| ES2375095T3 (es) | 2012-02-24 |
| CN102016586B (zh) | 2015-01-21 |
| CN102016586A (zh) | 2011-04-13 |
| CA2718245A1 (en) | 2009-09-17 |
| CA2718245C (en) | 2017-04-18 |
| MY156432A (en) | 2016-02-26 |
| JP2011513759A (ja) | 2011-04-28 |
| US20110076671A1 (en) | 2011-03-31 |
| EP2269069A1 (en) | 2011-01-05 |
| EP2101177A1 (en) | 2009-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12339282B2 (en) | Coronavirus antibody detection kit based on magnetic particle chemiluminescence | |
| Katz et al. | ELISA for detection of group-common and virus-specific antibodies in human and simian sera induced by herpes simplex and related simian viruses | |
| OBEL et al. | Serological and clinical findings in patients with serological evidence of reactivated Epstein‐Barr virus infection | |
| Karray et al. | Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia | |
| KR102433569B1 (ko) | 마이코플라즈마 뉴모니아의 면역학적 검출법 및 키트 | |
| JPH0614053B2 (ja) | ヒトサイトメガロウィルス特異的ＩｇＭの検出方法及びそのための手段 | |
| CN105866422B (zh) | 用于评估机体发生人巨细胞病毒活动性感染风险的方法及相关的试剂盒 | |
| JP5592277B2 (ja) | エプスタイン−バーウイルス（ｅｂｖ）再活性化のインビトロ診断のためのｚｅｂｒａタンパク質由来合成ペプチドの使用 | |
| CN118883927A (zh) | 一种用于检测抗体针对eb病毒衣壳抗原亲和力的试剂盒 | |
| JPH07209302A (ja) | Ｅｂｖに対する抗体の検出用診断試薬 | |
| McRAE et al. | Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection | |
| WO1997005488A1 (en) | Herpes simplex virus diagnostics | |
| US6337180B1 (en) | Peptide reagent enabling a primary Epstein-Barr virus infection to be detected by testing for the corresponding antibodies, and method for using this reagent | |
| JPH11500226A (ja) | 抗体産生の検出 | |
| KR101438530B1 (ko) | 위암 진단용 바이오 마커 조성물 및 이를 이용한 위암 진단 방법 | |
| JPWO2017065261A1 (ja) | ヒトパルボウイルスｂ１９抗原および抗体の同時検出方法及びキット | |
| EP0993616B1 (fr) | Reactif de detection et suivi des infections virales | |
| Kasubi et al. | A branched, synthetic oligopeptide corresponding to a region of glycoprotein G of HSV-1 reacts sensitively and specifically with HSV-1 antibodies in an ELISA | |
| WO2022053944A1 (en) | Immunoassay for the detection of antibodies against merkel cell polyomavirus (mcpyv) using synthetic peptides | |
| Geltosky et al. | Use of a synthetic peptide‐based elisa for the diagnosis of infectious mononucleosis and other diseases | |
| US9915662B2 (en) | Protein microarray for characterizing the specificity of the monoclonal immunoglobulins of MGUS or myeloma patients | |
| JP2002306164A (ja) | エボラウイルスを認識するモノクローナル抗体 | |
| AU2004290800B2 (en) | Methods and means relating to hepatitis B infection | |
| US20070054264A1 (en) | Methods and means relating to hepatitis b infection | |
| IT202300024003A1 (it) | Peptidi sintetici e loro uso in diagnostica per rilevare gli anticorpi contro il virus polioma delle cellule di merkel (mcpyv) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140715 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140731 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5592277 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |